ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
62.30
-4.00 (-6.03%)
At close: May 12, 2025, 4:00 PM
61.75
-0.55 (-0.88%)
After-hours: May 12, 2025, 7:57 PM EDT
ANI Pharmaceuticals Revenue
ANI Pharmaceuticals had revenue of $197.12M in the quarter ending March 31, 2025, with 43.43% growth. This brings the company's revenue in the last twelve months to $674.07M, up 30.26% year-over-year. In the year 2024, ANI Pharmaceuticals had annual revenue of $614.38M with 26.20% growth.
Revenue (ttm)
$674.07M
Revenue Growth
+30.26%
P/S Ratio
1.80
Revenue / Employee
$751,469
Employees
897
Market Cap
1.25B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 614.38M | 127.56M | 26.20% |
Dec 31, 2023 | 486.82M | 170.43M | 53.87% |
Dec 31, 2022 | 316.39M | 100.25M | 46.38% |
Dec 31, 2021 | 216.14M | 7.66M | 3.67% |
Dec 31, 2020 | 208.48M | 1.93M | 0.93% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ANIP News
- 9 hours ago - ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ - GlobeNewsWire
- 3 days ago - ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance - GlobeNewsWire
- 6 days ago - ANI Pharmaceuticals: A Short-Term Buying Opportunity - Seeking Alpha
- 7 days ago - ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model - GlobeNewsWire
- 4 weeks ago - ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - GlobeNewsWire
- 6 weeks ago - ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - GlobeNewsWire
- 7 weeks ago - ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets - GlobeNewsWire